Psychiatry Research
Volume 136, Issue 2 , Pages 211-221 , 15 September 2005

Validation of the Investigator's Assessment Questionnaire, a new clinical tool for relative assessment of response to antipsychotics in patients with schizophrenia and schizoaffective disorder

  • Rajiv Tandon

      Affiliations

    • Department of Psychiatry (Adjunct), University of Florida, Gainesville, FL, USA
    • ,
  • Robert F. DeVellis

      Affiliations

    • Department of Health Behavior and Health Education, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
    • ,
  • Jian Han

      Affiliations

    • Biostatistics and Programming, Bristol-Myers Squibb Company, Wallingford, CT, USA
    • ,
  • Hong Li

      Affiliations

    • Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660, USA
    • Corresponding Author InformationCorresponding author. Tel.: +1 203 677 5787; fax: +1 203 677 5797.
    • ,
  • Sophia Frangou

      Affiliations

    • Section of Neurobiology of Psychosis, Institute of Psychiatry, London, UK
    • ,
  • Serdar Dursun

      Affiliations

    • Neuroscience and Psychiatry Unit, University of Manchester, Manchester, UK
    • ,
  • IAQ Validation Study Group
    • ,
  • Jean-Noel Beuzen

      Affiliations

    • International Medical Affairs, Bristol-Myers Squibb Company, Braine-I'Alleud, Belgium
    • ,
  • William Carson

      Affiliations

    • Global Development and Commercialization, Otsuka America Pharmaceutical Inc., Princeton, NJ, USA
    • ,
  • Patricia K. Corey-Lisle

      Affiliations

    • Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660, USA
    • ,
  • Bruno Falissard

      Affiliations

    • Department of Public Health, Hôpital Paul Brousse, Villejuif, France
    • ,
  • Darlene N. Jody

      Affiliations

    • Global Medical Marketing, Bristol-Myers Squibb Company, Princeton, NJ, USA
    • ,
  • Mary J. Kujawa

      Affiliations

    • US Medical Affairs, Bristol-Myers Squibb Company, Princeton, NJ, USA
    • ,
  • Gilbert L'Italien

      Affiliations

    • Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660, USA
    • ,
  • Ronald N. Marcus

      Affiliations

    • Global Clinical Research, Bristol-Myers Squibb Company, Wallingford, CT, USA
    • ,
  • Robert D. McQuade

      Affiliations

    • Global Medical Marketing, Bristol-Myers Squibb Company, Princeton, NJ, USA
    • ,
  • Saurabh Ray

      Affiliations

    • Global Epidemiology and Outcomes Research, Bristol-Myers Squibb Company, 5 Research Parkway, Wallingford, CT 06492-7660, USA
    • ,
  • Pascal Van Peborgh

      Affiliations

    • Medical Affairs, Bristol-Myers Squibb Company, Lounslow, UK

Received 30 August 2004 ,Revised 17 March 2005 ,Accepted 26 May 2005.

References 

  1. American Diabetes Association , American Psychiatric Association , American Association of Clinical Endocrinologists , North American Association for the Study of Obesity . Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596–601
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Revision DSM-IV-TR. Arlington, VA: APA; 2000;
  3. Arana GW. An overview of side effects caused by typical antipsychotics. Journal of Clinical Psychiatry. 2000;61(Suppl 8):5–11
  4. Bridler R, Umbricht D. Atypical antipsychotics in the treatment of schizophrenia. Swiss Medical Weekly. 2003;133:63–76
  5. Busch AB. Validity, reliability and other key concepts in outcome assessment and services research. In:  IsHak WW,  Burt T,  Sederer LI editor. Outcome Measurement in Psychiatry: a Critical Review. Washington, DC: American Psychiatric Publishing, Inc.; 2002;p. 35–55
  6. Byerly MJ, Weber MT, Brooks DL, Snow LR, Worley MA, Lescouflair E. Antipsychotic medications and the elderly: effects on cognition and implications for use. Drugs and Aging. 2001;18:45–61
  7. Collaborative Working Group on Clinical Trial Evaluations. Measuring outcome in schizophrenia: differences among the atypical antipsychotics. Journal of Clinical Psychiatry. 1998;59:3–9
  8. David SR, Taylor CC, Kinon BJ, Breier A. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia. Clinical Therapeutics. 2000;22:1085–1096
  9. Dickson RA, Glazer WM. Neuroleptic-induced hyperprolactinemia. Schizophrenia Research. 1999;35:S75–S86(Suppl)
  10. Freedman R. Schizophrenia. New England Journal of Medicine. 2003;349:1738–1749
  11. Guy, W., 1976. ECDEU Assessment Manual for Psychopharmacology-Revised. DHEW Pub. No. ADM 76-338, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, Rockville, MD, pp. 218–222.
  12. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychological Medicine. 1983;13:177–183
  13. Jaffe AB, Levine J. Efficacy and effectiveness of first- and second-generation antipsychotics in schizophrenia. Journal of Clinical Psychiatry. 2003;64(Suppl 17):3–6
  14. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy. 2004;24:1759–1783
  15. Kane JM. Schizophrenia. New England Journal of Medicine. 1996;334:34–41
  16. Kane JM. Extrapyramidal side effects are unacceptable. European Neuropsychopharmacology. 2001;11:S397–S403
  17. Kay SR, Fiszbein A, Opler LA. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophrenia Bulletin. 1987;13:261–276
  18. Lambert TJ, Castle DJ. Pharmacological approaches to the management of schizophrenia. Medical Journal of Australia. 2003;178:S57–S61(Suppl)
  19. McDowell I, Newell C. The theoretical and technical foundations of health measurement. In: Measuring Health: a Guide to Rating Scales and Questionnaires. 2nd ed.. New York: Oxford University Press; 1996;p. 10–46
  20. Nasrallah HA, Targum SD, Tandon R, McCombs JS, Ross R. Defining and measuring clinical effectiveness in the treatment of schizophrenia. Psychiatric Services. 2005;56:273–282
  21. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychological Reports. 1962;10:799–812
  22. Rachid F, Bertschy G, Bondolfi G, Aubry JM. Possible induction of mania or hypomania by atypical antipsychotics: an updated review of reported cases. Journal of Clinical Psychiatry. 2004;65:1537–1545
  23. Stanniland C, Taylor D. Tolerability of atypical antipsychotics. Drug Safety. 2000;22:195–214
  24. Tandon R. Safety and tolerability: how do newer generation “atypical” antipsychotics compare?. Psychiatric Quarterly. 2002;73:297–311
  25. Tandon, R., Marcus, R., Carson, W., Jody, D., Pans, M., Riera, L., Liston, H., Nyilas, M., submitted for publication. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial with Aripiprazole (BETA).
  26. van der Linden WJ. Classical test theory. In:  Kempt-Leonard K editors. Encyclopedia of Social Measurement. Oxford, UK: Elsevier; 2005;p. 301–307
  27. Wirshing DA. Schizophrenia and obesity: impact of antipsychotic medications. Journal of Clinical Psychiatry. 2004;65(Suppl 18):13–26

PII: S0165-1781(05)00152-6

doi: 10.1016/j.psychres.2005.05.006

Psychiatry Research
Volume 136, Issue 2 , Pages 211-221 , 15 September 2005

Article Tools

* Image Usage & Resolution